The spinout is working on a robotic arm for removing gastrointestinal cancer tumours without the need for an operational incision.

EndoMaster, a Singapore-based medtech developer spun out from National University of Singapore (NUS) and Nanyang Technological University (NTU), has secured S$20.5m ($15.1m) in series B funding, the Business Times reported today.

The investors in the round have not been identified.

EndoMaster has built a robotic arm that removes cancer tumours from gastrointestinal areas around the stomach by accessing the body’s existing openings rather than using an operational incision.

The business claims clinical tests suggested the tool could bring the frequency…